Phospholamban pentamers attenuate PKA-dependent phosphorylation of monomers

Journal of Molecular and Cellular Cardiology

Volumn 80, Issue , 2015, Pages 90-97

  Wittmann, Tanja ^a   Lohse, Martin J ^a   Schmitt, Joachim P ^a,b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Phospholamban; Protein kinase A; Sarcoplasmic reticulum; SERCA2a

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); ADENYLATE CYCLASE; CYCLIC AMP DEPENDENT PROTEIN KINASE; DOBUTAMINE; FORSKOLIN; MONOMER; PHOSPHOLAMBAN; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; CALCIUM BINDING PROTEIN; PROTEIN BINDING;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; HEART MUSCLE CELL; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; MEMBRANE VESICLE; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STOICHIOMETRY; WESTERN BLOTTING; ANIMAL; CHEMISTRY; GENETICS; HEK293 CELL LINE; METABOLISM; MUTATION; PHOSPHORYLATION; PROTEIN MULTIMERIZATION; PROTEIN STABILITY; PROTEIN TRANSPORT;

ANIMALS; CALCIUM-BINDING PROTEINS; CYCLIC AMP-DEPENDENT PROTEIN KINASES; HEK293 CELLS; HUMANS; MICE; MUTATION; MYOCYTES, CARDIAC; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN MULTIMERIZATION; PROTEIN STABILITY; PROTEIN TRANSPORT; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES;

EID: 84920973947     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2014.12.020     Document Type: Article

References (38)

1. Bers D.M. Calcium fluxes involved in control of cardiac myocyte contraction. Circ Res 2000, 87:275-281.
2. Kranias E.G., Hajjar R.J. Modulation of cardiac contractility by the phopholamban/serca2a regulatome. Circ Res 2012, 110:1646-1660.
3. Schmitt J.P., Kamisago M., Asahi M., Li G.H., Ahmad F., Mende U., et al. Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban. Science 2003, 299:1410-1413.
4. Haghighi K., Kolokathis F., Pater L., Lynch R.A., Asahi M., Gramolini A.O., et al. Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. J Clin Invest 2003, 111:869-876.
5. Haghighi K., Kolokathis F., Gramolini A.O., Waggoner J.R., Pater L., Lynch R.A., et al. A mutation in the human phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy. Proc Natl Acad Sci U S A 2006, 103:1388-1393.
6. Kranias E.G. Regulation of Ca2+ transport by cyclic 3',5'-amp-dependent and calcium-calmodulin-dependent phosphorylation of cardiac sarcoplasmic reticulum. Biochim Biophys Acta 1985, 844:193-199.
7. Wegener A.D., Jones L.R. Phosphorylation-induced mobility shift in phospholamban in sodium dodecyl sulfate-polyacrylamide gels. Evidence for a protein structure consisting of multiple identical phosphorylatable subunits. J Biol Chem 1984, 259:1834-1841.
8. Kimura Y., Kurzydlowski K., Tada M., MacLennan D.H. Phospholamban inhibitory function is activated by depolymerization. J Biol Chem 1997, 272:15061-15064.
9. Zvaritch E., Backx P.H., Jirik F., Kimura Y., de Leon S., Schmidt A.G., et al. The transgenic expression of highly inhibitory monomeric forms of phospholamban in mouse heart impairs cardiac contractility. J Biol Chem 2000, 275:14985-14991.
10. Jones L.R., Cornea R.L., Chen Z. Close proximity between residue 30 of phospholamban and cysteine 318 of the cardiac Ca2+ pump revealed by intermolecular thiol cross-linking. J Biol Chem 2002, 277:28319-28329.
11. Toyoshima C., Asahi M., Sugita Y., Khanna R., Tsuda T., MacLennan D.H. Modeling of the inhibitory interaction of phospholamban with the Ca2+ ATPase. Proc Natl Acad Sci U S A 2003, 100:467-472.
12. Akin B.L., Hurley T.D., Chen Z., Jones L.R. The structural basis for phospholamban inhibition of the calcium pump in sarcoplasmic reticulum. J Biol Chem 2013, 288:30181-30191.
13. Stokes D.L., Pomfret A.J., Rice W.J., Glaves J.P., Young H.S. Interactions between Ca2+-ATPase and the pentameric form of phospholamban in two-dimensional co-crystals. Biophys J 2006, 90:4213-4223.
14. Glaves J.P., Trieber C.A., Ceholski D.K., Stokes D.L., Young H.S. Phosphorylation and mutation of phospholamban alter physical interactions with the sarcoplasmic reticulum calcium pump. J Biol Chem 2011, 405:707-723.
15. Chu G., Lester J.W., Young K.B., Luo W., Zhai J., Kranias E.G. A single site (Ser16) phosphorylation in phospholamban is sufficient in mediating its maximal cardiac responses to beta -agonists. J Biol Chem 2000, 275:38938-38943.
16. Bilezikjian L.M., Kranias E.G., Potter J.D., Schwartz A. Studies on phosphorylation of canine cardiac sarcoplasmic reticulum by calmodulin-dependent protein kinase. Circ Res 1981, 49:1356-1362.
17. Luo W., Chu G., Sato Y., Zhou Z., Kadambi V.J., Kranias E.G. Transgenic approaches to define the functional role of dual site phospholamban phosphorylation. J Biol Chem 1998, 273:4734-4739.
18. Said M., Mundiña-Weilenmann C., Vittone L., Mattiazzi A. The relative relevance of phosphorylation of the Thr17 residue of phospholamban is different at different levels of β-adrenergic stimulation. Pflugers Arch 2002, 444:801-809.
19. Kuschel M., Karczewski P., Hempel P., Schlegel W.-P., Krause E.-G., Bartel S. Ser16 prevails over Thr17 phospholamban phosphorylation in the β-adrenergic regulation of cardiac relaxation. Am J Physiol Heart Circ Physiol 1999, 276:H1625-H1633.
20. Vittone L., Mundina C., Chiappe de Cingolani G., Mattiazzi A. cAMP and calcium-dependent mechanisms of phospholamban phosphorylation in intact hearts. Am J Physiol 1990, 258:H318-H325.
21. Bartel S., Vetter D., Schlegel W.P., Wallukat G., Krause E.G., Karczewski P. Phosphorylation of phospholamban at threonine-17 in the absence and presence of beta-adrenergic stimulation in neonatal rat cardiomyocytes. J Mol Cell Cardiol 2000, 32:2173-2185.
22. Mundiña-Weilenmann C., Vittone L., Ortale M., de Cingolani G.C., Mattiazzi A. Immunodetection of phosphorylation sites gives new insights into the mechanisms underlying phospholamban phosphorylation in the intact heart. J Biol Chem 1996, 271:33561-33567.
23. Ceholski D.K., Trieber C.A., Holmes C.F., Young H.S. Lethal, hereditary mutants of phospholamban elude phosphorylation by protein kinase A. J Biol Chem 2012, 287:26596-26605.
24. Schmitt J.P., Ahmad F., Lorenz K., Hein L., Schulz S., Asahi M., et al. Alterations of phospholamban function can exhibit cardiotoxic effects independent of excessive sarcoplasmic reticulum Ca2+-ATPase inhibition. Circulation 2009, 119:436-444.
25. Münch G., Bölck B., Karczewski P., Schwinger R.H.G. Evidence for calcineurin-mediated regulation of serca2a activity in human myocardium. J Mol Cell Cardiol 2002, 34:321-334.
26. Zamoon J., Mascioni A., Thomas D.D., Veglia G. NMR solution structure and topological orientation of monomeric phospholamban in dodecylphosphocholine micelles. Biophys J 2003, 85:2589-2598.
27. Karim C.B., Marquardt C.G., Stamm J.D., Barany G., Thomas D.D. Synthetic null-cysteine phospholamban analogue and the corresponding transmembrane domain inhibit the Ca-ATPase. Biochemistry 2000, 39:10892-10897.
28. Hoshijima M., Ikeda Y., Iwanaga Y., Minamisawa S., Date M.O., Gu Y., et al. Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac raav gene delivery. Nat Med 2002, 8:864-871.
29. Seidel K., Andronesi O.C., Krebs J., Griesinger C., Young H.S., Becker S., et al. Structural characterization of Ca(2+)-ATPase-bound phospholamban in lipid bilayers by solid-state nuclear magnetic resonance (NMR) spectroscopy. Biochemistry 2008, 47:4369-4376.
30. Fujii J., Maruyama K., Tada M., MacLennan D.H. Expression and site-specific mutagenesis of phospholamban. Studies of residues involved in phosphorylation and pentamer formation. J Biol Chem 1989, 264:12950-12955.
31. Toyofuku T., Kurzydlowski K., Tada M., MacLennan D.H. Amino acids Glu2 to Ile18 in the cytoplasmic domain of phospholamban are essential for functional association with the Ca(2+)ATPase of sarcoplasmic reticulum. J Biol Chem 1994, 269:3088-3094.
32. Hughes E., Clayton J.C., Middleton D.A. Probing the oligomeric state of phospholamban variants in phospholipid bilayers from solid-state NMR measurements of rotational diffusion rates. Biochemistry 2005, 44:4055-4066.
33. Akin B.L., Chen Z., Jones L.R. Superinhibitory phospholamban mutants compete with Ca2+ for binding to serca2a by stabilizing a unique nucleotide-dependent conformational state. J Biol Chem 2010, 285:28540-28552.
34. Cornea R.L., Jones L.R., Autry J.M., Thomas D.D. Mutation and phosphorylation change the oligomeric structure of phospholamban in lipid bilayers. Biochemistry 1997, 36:2960-2967.
35. Chiesis M., Schwaller R. Involvement of electrostatic phenomena in phospholamban-induced stimulation of Ca uptake into cardiac sarcoplasmic reticulum. FEBS Lett 1989, 244:241-244.
36. Wegener A.D., Simmerman H.K.B., Lindemann J.P., Jones L.R. Phospholamban phosphorylation in intact ventricles. J Biol Chem 1989, 264:11468-11474.
37. Robia S.L., Campbell K.S., Kelly E.M., Hou Z., Winters D.L., Thomas D.D. Forster transfer recovery reveals that phospholamban exchanges slowly from pentamers but rapidly from the serca regulatory complex. Circ Res 2007, 101:1123-1129.
38. Masterson L.R., Cheng C., Yu T., Tonelli M., Kornev A., Taylor S.S., et al. Dynamics connect substrate recognition to catalysis in protein kinase A. Nat Chem Biol 2010, 6:821-828.